
Joseph Irwin Friedman MD
Geriatric Psychiatry, Neuropsychiatry, Clinical Informatics
1. Director of Delirium Services for the Mount Sinai Health System: The Mount Sinai System of Hospital, New York, NY. 2. Professor: Department of Psychiatry; Icahn School of Medicine at Mount Sinai Hospital, New York, NY 10029. 3. Professor: Department of Neuroscience; Icahn School of Medicine at Mount Sinai Hospital, New York, NY 10029.
Join to View Full Profile
1450 Maidson AvenueFifth floor - office 570CNew York, NY 10029
Phone+1 212-241-7901
Fax+1 631-623-6439
Dr. Friedman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joseph Friedman is a psychiatrist based in New York, NY, with subspecialties in geriatric psychiatry, neuropsychiatry, and clinical informatics. He completed his psychiatry residency at the Icahn School of Medicine at Mount Sinai in 1995 after graduating from the Medical College of Wisconsin in 1992. Dr. Friedman has authored several publications, including papers in renowned journals such as The New England Journal of Medicine and The American Journal of Psychiatry, and his work has been cited across multiple publications. His research interests include dementia-related psychosis and the role of clinical genetic testing in psychiatry. Additionally, he has been involved in clinical trials focusing on cognitive enhancement and treatment augmentation for schizophrenia.
Education & Training
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 1992 - 1995
- Medical College of WisconsinClass of 1992
Certifications & Licensure
- NY State Medical License 1994 - 2027
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia Start of enrollment: 2004 Oct 01
- Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Start of enrollment: 2000 Feb 01
- Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia Start of enrollment: 2005 Jan 01
Publications & Presentations
PubMed
- 1 citationsMachine Learning Multimodal Model for Delirium Risk Stratification.Joseph I Friedman, Prathamesh Parchure, Fu-Yuan Cheng, Weijia Fu, Satyanarayana Cheertirala
JAMA Network Open. 2025-05-01 - 1 citationsPimavanserin in Dementia-Related PsychosisJoseph I. Friedman
The New England Journal of Medicine. 2021-07-21 - 10 citationsA Multi‐Phase Quality Improvement Initiative for the Treatment of Active Delirium in Older PersonsJoseph I. Friedman, Lihua Li, Sapina Kirpalani, Xiaobo Zhong, Robert Freeman
Journal of the American Geriatrics Society. 2021-01-01
Press Mentions
- AI model provides ‘huge’ benefit for delirium detection among hospitalized older adultsJuly 9th, 2025
- Hospital bosses love AI. Doctors and nurses are worriedAugust 10th, 2023
- Native Americans Left Out of 'Deaths of Despair' ResearchFebruary 1st, 2023
- Join now to see all
Grant Support
- Pimozide Augmentation Of Clozapine In SchizophreniaNational Institute Of Mental Health2004–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: